Emerging Stocks Down Under 4 January 2022: Pharmaxis, 8Common, Peppermint Innovation

Pharmaxis: It’s all about the news flow

In today’s edition of Emerging Stocks Down Under, headquartered in the Northern Sydney suburb of Frenchs Forest, Pharmaxis is an early-stage drug developer at its core. The thing that sets Pharmaxis apart from other companies in this stage of development is the two products approved and making their way through global distribution channels. To be clear, Pharmaxis is not yet profitable, but it is on its way after these two products saw strong approval and distribution growth in FY21.It seems likely shareholders will be in for further dilution, though, despite the one year of financial runway the company had as of 30 June 2021. Yet, at its current valuation, we believe the rewards far outweigh the risk.


Also in today’s edition, a look at software developer 8Common (ASX: 8CO) and remittance and digital payments services Peppermint Innovation (ASX: PIL).


Click here to read the previous edition of Emerging Stocks Down Under published 21 December 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.

[pdf-embedder url=’https://stocksdownunder.com/wp-content/uploads/securepdfs/2022/01/Emerging-Stocks-Down-Under-Edition-66-04-01-2022-8CO-PIL-PXS.pdf’ toolbar=’both’ toolbarfixed=’on’]